Brian Gallagher

Biography

Brian M. Gallagher, Jr., PhD is a Partner at SR One Ltd. He established the SR One Boston office in 2010, and is focused on building innovative therapeutic and life science companies. In addition to Navitor, Dr. Gallagher currently represents SR One on the boards of Aileron Therapeutics, CalciMedica, Constellation Pharmaceuticals, Nimbus Discovery, RaNA Therapeutics, and River Vision. He previously led the firm’s investments in Dicerna Pharmaceuticals (NASDAQ: DRNA) and SpringLeaf Therapeutics. Dr. Gallagher has more than 15 years of investing, business development, operational and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals, where he was responsible for corporate development and operations, as well as post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Dr. Gallagher was with Alantos Pharmaceuticals, where he played key roles in R&D and business development activities and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. Dr. Gallagher began his career in R&D at the Japanese pharma Eisai, where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas. He is an inventor on over 25 patents and patent applications and is the senior author of a number of scientific publications. He currently serves on the industry advisory boards for New York University Medical School and the National Brain Tumor Society and is a mentor for MassBio MassCONNECT and a peer reviewer/editorial board member for numerous journals and research funding authorities. Dr. Gallagher received his BS in Chemistry from The University of Massachusetts, where he was a Shapiro scholar, and his MS and PhD degrees in Organic Chemistry from The University of Michigan.

Research Interest

Immunology, Therapeutics, Molecular Biology